Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Nov 4, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	158	191	199	413	264	133
Market Cap Growth	-21.52%	-4.09%	-51.84%	56.44%	98.01%	19.78%
Enterprise Value	121	151	134	349	228	101
Last Close Price	0.84	1.09	1.17	2.45	1.76	0.89
PE Ratio	-	-8.76	-7.56	-9.37	-12.79	-11.06
PS Ratio	24.46	21.32	13.53	95.13	144.57	37.93
PB Ratio	2.32	3.08	2.76	4.54	2.78	1.20
P/FCF Ratio	-8.43	-6.52	307.85	-17.28	-13.32	-4.12
P/OCF Ratio	-8.55	-6.68	187.79	-17.53	-13.36	-4.17
EV/Sales Ratio	19.62	16.88	9.11	80.50	124.70	28.82
EV/EBITDA Ratio	-6.85	-7.36	-6.15	-7.23	-9.33	-3.29
EV/EBIT Ratio	-6.64	-7.12	-5.95	-7.10	-8.61	-3.00
EV/FCF Ratio	-6.56	-5.17	207.31	-14.62	-11.49	-3.13
Debt / Equity Ratio	0.04	0.05	0.05	0.03	0.04	0.05
Debt / FCF Ratio	-0.13	-0.10	6.03	-0.12	-0.19	-0.16
Asset Turnover	0.06	0.08	0.10	0.03	0.02	0.03
Quick Ratio	2.54	2.02	3.06	2.32	5.35	4.78
Current Ratio	2.64	2.14	3.16	2.37	5.66	8.86
Return on Equity (ROE)	-35.04%	-32.07%	-32.37%	-46.52%	-20.05%	-11.62%
Return on Assets (ROA)	-12.86%	-11.80%	-9.44%	-21.78%	-14.16%	-18.59%
Return on Capital (ROIC)	-19.09%	-18.82%	-16.60%	-31.93%	-15.35%	-20.02%
Earnings Yield	-15.27%	-11.26%	-13.21%	-10.42%	-7.82%	-8.78%
FCF Yield	-14.10%	-15.33%	0.32%	-5.79%	-7.51%	-24.29%
Buyback Yield / Dilution	-6.05%	-1.69%	-3.22%	-9.64%	-3.10%	-14.68%
Total Shareholder Return	-6.05%	-1.69%	-3.22%	-9.64%	-3.10%	-14.68%

Source: S&P Capital IQ. Standard template. Financial Sources.